Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone

Stine Andersen*, Julie Birkmose Axelsen, Steffen Ringgaard, Jens Randel Nyengaard, Signe Holm Nielsen, Federica Genovese, Morten Asser Karsdal, Janus Adler Hyldebrandt, Charlotte Brandt Sørensen, Frances S. de Man, Harm Jan Bogaard, Jens Erik Nielsen-Kudsk, Asger Andersen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

215 Downloads (Pure)


Cardiac fibrosis contributes to the development of heart failure in pulmonary hypertension. We aimed to assess the development of fibrosis and the effects of treatment with the anti-fibrotic agent pirfenidone in pressure overload induced right ventricular (RV) failure. Wistar rat weanlings were randomized to pulmonary trunk banding (PTB) or sham surgery. One week after the procedure, PTB rats were randomized into two groups with either six weeks on standard chow or treatment with pirfenidone mixed in chow (700 mg/kg/day). RV hemodynamic effects were evaluated by echocardiography, cardiac magnetic resonance imaging (MRI), and pressure-volume measurements. Sections from the isolated RV, left ventricle, and septum were sampled systematically; stereological point grids and the nucleator were used to estimate volume of fibrosis and cardiac hypertrophy, respectively. PTB caused RV failure in all rats subjected to the procedure. The volume fraction of fibrosis in the RV increased threefold in PTB rats corresponding to a sixfold increase in total volume of RV fibrosis. Volume fraction of fibrosis and total volume of fibrosis also increased in the septum and in the left ventricle. Pirfenidone reduced body weight but did not improve RV hemodynamics or reduce cardiac fibrosis. RV cardiomyocyte profile area was increased twofold in PTB rats without any effect of pirfenidone. RV pressure overload after PTB induced not only RV but also septal and left ventricular fibrosis assessed by stereology. Treatment with pirfenidone reduced body weight but did not reduce the development of cardiac fibrosis or delay the progression of RV failure.

Original languageEnglish
JournalPulmonary Circulation
Issue number2
Pages (from-to)1-13
Number of pages13
Publication statusPublished - 2019


  • Right ventricular function and dysfunction
  • Remodeling
  • Animal models


Dive into the research topics of 'Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone'. Together they form a unique fingerprint.

Cite this